Actuate Therapeutics Inc (ACTU)
NASDAQ: ACTU
· Real-Time Price · USD
8.72
0.11 (1.28%)
At close: Sep 04, 2025, 3:59 PM
8.72
0.00%
After-hours: Sep 04, 2025, 04:10 PM EDT
1.28% (1D)
| Bid | 8.22 |
| Market Cap | 180.88M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -24.68M |
| EPS (ttm) | -3.11 |
| PE Ratio (ttm) | -2.8 |
| Forward PE | -6.73 |
| Analyst | Buy |
| Ask | 9.05 |
| Volume | 86,028 |
| Avg. Volume (20D) | 100,535 |
| Open | 8.66 |
| Previous Close | 8.61 |
| Day's Range | 8.56 - 9.22 |
| 52-Week Range | 5.47 - 11.99 |
| Beta | 0.15 |
About ACTU
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol ACTU
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for ACTU stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts1 month ago
+0.48%
ACTU stock has given up its prior gain. Actuate Th...
Unlock content with
Pro Subscription
1 month ago
+0.48%
Actuate Therapeutics shares are trading higher after the company announced it will initiate the planning of its Phase 2 trial of Elraglusib.